ArticleJournal of translational medicine2026
Time-dependent Lactiplantibacillus plantarum (LP) AS21 intervention enhances mesalazine efficacy by modulating gut microbiota and host immunometabolic responses in DSS-induced colitis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEvidence suggests that Lactiplantibacillus plantarum (LP) exerts a therapeutic effect in ulcerative colitis (UC). However, the temporal dynamics underlying the influence of LP AS21 on the efficacy of mesalazine (MSA) treatment in UC remain poorly defined. This study aims to elucidate the time-dependent impact of LP AS21 on MSA-mediated therapeutic outcomes in UC.
methodsColitis was induced in female C57BL/6J mice using 3% DSS for one week, followed by a three-week treatment phase with weekly evaluations. Disease progression was monitored via body weight, DAI, and colon length measurement. Histology, serum markers, and immunohistochemistry were used to assess inflammation, oxidative stress, and epithelial integrity at multiple time points. Subsequently, intestinal contents were collected for 16 S rRNA gene sequencing and untargeted LC-MS metabolomics to track temporal microbial and metabolic dynamics. Correlation analyses were performed to assess the association of specific microbiota and metabolites with cytokines and antioxidant markers.
resultsTime-dependent LP AS21 intervention significantly modulated the therapeutic efficacy of MSA in DSS-induced colitis. LP treatment during the second and third weeks promoted recovery of body weight, improved DAI, and restored mucosal architecture compared with the first week. The temporal administration of LP modulated the host response to MSA treatment by enhancing antioxidant defenses, including catalase, superoxide dismutase, and glutathione, while suppressing pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IFN-γ, with the most pronounced effects observed during the second and third weeks. Additionally, DSS administration increased microbial richness and promoted opportunistic pro-inflammatory taxa, including Akkermansia and Proteobacteria. Extended LP intervention influenced MSA efficacy by partial restoration of gut microbial diversity and enrichment of beneficial taxa. This microbial restoration was associated with normalization of the metabolic profile, especially in steroid biosynthesis and glycerophospholipid pathways. Key metabolites, including 5-aminopentanoic acid, GpCho (16:0/20:5), and 25-hydroxycholecalciferol, were significantly restored. These metabolite-driven changes in glycerophospholipid and steroid metabolism correlated with improved redox homeostasis and immune regulation, highlighting their potential as biomarkers to assess time-dependent therapeutic responses of LP-augmented MSA treatment in UC.
conclusionLP AS21 intervention improves MSA efficacy in DSS-induced colitis by modulating immunometabolic networks and gut microbiota, with treatment duration critically shaping therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.